[SCHEDULE 13G/A] Cidara Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Cidara Therapeutics' Schedule 13G/A discloses that Vivo Opportunity Fund Holdings, L.P. (and its general partner Vivo Opportunity, LLC) beneficially owns 1,175,796 shares of Cidara common stock, representing 4.6% of the outstanding class. Vivo Opportunity Cayman Fund, L.P. (and its general partner Vivo Opportunity Cayman, LLC) beneficially owns 135,629 shares, representing 0.5% of the class. Each reporting person reports sole voting and sole dispositive power over the shares they hold of record through the funds. The filing states the holdings were not acquired to change or influence control of the issuer and ties beneficial ownership to the funds and their general partners as disclosed in the issuer's public filings.

Positive

• Provides clear, itemized disclosure of beneficial ownership for multiple related entities, improving transparency for investors and regulators.
• Reports sole voting and dispositive power for the reporting persons, removing ambiguity about who controls the reported shares.

Negative

• None.

Insights

Financial Analyst

TL;DR Vivo Opportunity reports a 4.6% stake via its U.S. fund and a 0.5% stake via its Cayman fund, a non-controlling disclosure.

The Schedule 13G/A is a routine beneficial ownership disclosure showing material but non-controlling positions: 1,175,796 shares (4.6%) held by Vivo Opportunity Fund Holdings, L.P. and 135,629 shares (0.5%) held by the Cayman fund. Both funds' general partners report sole voting and dispositive power over the shares held of record. Because the largest reported position remains under 5%, this filing does not signal a change-in-control intent and is primarily informative for shareholder registries and market transparency.

Corporate Governance Expert

TL;DR The filing documents transparent ownership and confirms no intent to influence control, consistent with a passive investor posture.

The statement clarifies ownership structures—U.S. and Cayman limited partnerships with their respective general partners—and confirms that reported securities are held of record by the funds with sole voting and dispositive authority attributed to the reporting persons. The certification that the shares were not acquired to change control aligns with the regulatory purpose of a Schedule 13G/A and indicates this is a disclosure of passive holdings rather than an activist or control-seeking action.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Cidara Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

171757206

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Vivo Opportunity Fund Holdings, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,175,796.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,175,796.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,175,796.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The number represents shares of common stock, $0.0001 par value (the "Common Stock") of Cidara Therapeutics, Inc. (the "Issuer") held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. Based on 25,358,051 shares of Common Stock issued and outstanding as of August 6, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on August 7, 2025.

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Vivo Opportunity, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,175,796.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,175,796.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,175,796.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. Based on 25,358,051 shares of Common Stock issued and outstanding as of August 6, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on August 7, 2025.

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Vivo Opportunity Cayman Fund, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 135,629.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 135,629.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

135,629.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.5 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. Based on 25,358,051 shares of Common Stock issued and outstanding as of August 6, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on August 7, 2025.

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Vivo Opportunity Cayman, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 135,629.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 135,629.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

135,629.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.5 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. Based on 25,358,051 shares of Common Stock issued and outstanding as of August 6, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on August 7, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cidara Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 6310 Nancy Ridge Drive, Suite 101, San Diego, CA 92121
Item 2.
(a)	Name of person filing: Vivo Opportunity Fund Holdings, L.P. and its General Partner Vivo Opportunity, LLC Vivo Opportunity Cayman Fund, L.P. and its General Partner Vivo Opportunity Cayman, LLC
(b)	Address or principal business office or, if none, residence: 192 Lytton Avenue, Palo Alto, CA 94301
(c)	Citizenship: Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership. Vivo Opportunity, LLC is a Delaware limited liability company. Vivo Opportunity Cayman Fund, L.P. is a Cayman Islands limited partnership. Vivo Opportunity Cayman, LLC is a Cayman Islands limited liability company.
(d)	Title of class of securities: Common Stock, $0.0001 par value
(e)	CUSIP No.: 171757206
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Vivo Opportunity, LLC beneficially owns 1,175,796 shares of Common Stock. The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity Cayman, LLC beneficially owns 135,629 shares of Common Stock. The securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
(b)	Percent of class: Vivo Opportunity Fund Holdings, L.P.: 4.6% Vivo Opportunity, LLC: 4.6% Vivo Opportunity Cayman Fund, L.P.: 0.5% Vivo Opportunity Cayman, LLC.: 0.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Vivo Opportunity Fund Holdings, L.P.: 1,175,796 shares Vivo Opportunity, LLC: 1,175,796 shares Vivo Opportunity Cayman Fund, L.P.: 135,629 shares Vivo Opportunity Cayman, LLC: 135,629 shares
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: Vivo Opportunity Fund Holdings, L.P.: 1,175,796 shares Vivo Opportunity, LLC: 1,175,796 shares Vivo Opportunity Cayman Fund, L.P.: 135,629 shares Vivo Opportunity Cayman, LLC: 135,629 shares
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vivo Opportunity Fund Holdings, L.P.

Signature:	/s/ Kevin Dai
Name/Title:	Kevin Dai/Managing Member
Date:	08/12/2025

Vivo Opportunity, LLC

Signature:	/s/ Kevin Dai
Name/Title:	Kevin Dai/Managing Member
Date:	08/12/2025

Vivo Opportunity Cayman Fund, L.P.

Signature:	/s/ Kevin Dai
Name/Title:	Kevin Dai/Managing Member
Date:	08/12/2025

Vivo Opportunity Cayman, LLC

Signature:	/s/ Kevin Dai
Name/Title:	Kevin Dai/Managing Member
Date:	08/12/2025

FAQ

How many Cidara (CDTX) shares does Vivo Opportunity report owning?

Vivo Opportunity Fund Holdings, L.P. reports 1,175,796 shares and Vivo Opportunity Cayman Fund, L.P. reports 135,629 shares.

What percentage of CDTX does Vivo Opportunity own?

The U.S. fund's position is 4.6% of the class and the Cayman fund's position is 0.5% of the class, as reported.

Does Vivo Opportunity have voting control over the reported CDTX shares?

Yes. The filing states each reporting person has sole voting and sole dispositive power over the shares they report.

Was the stake reported as being acquired to change control of Cidara?

No. The filing includes a certification that the securities were not acquired and are not held to change or influence control of the issuer.

Which Cidara class and CUSIP does the filing cover?

The filing covers Cidara's Common Stock, $0.0001 par value with CUSIP 171757206.